Acanthosis nigricans: An extensive review
Keywords:
acanthosis nigricans (AN), insulin resistance, endocrine disorders, obesity, paraneoplastic syndrome, growth factors, hyperpigmentation, differential diagnosis.Abstract
Acanthosis nigricans (AN) is a velvety, hyperpigmentation of the skin that usually occurs in intertriginous areas. AN is most commonly associated with benign disorders like diabetes, insulin resistance, endocrinopathies and exogenous medications, but can be a valid cutaneous marker of a wide range of internal malignancies, which makes it important for the physicians across specialties to have awareness about it. With an increase in the prevalence of obesity and diabetes in recent decades, the prevalence of AN has also shown a significant increase. This article will review in detail the epidemiology, pathophysiology, clinical features and treatment of acanthosis nigricans in the light of the literatureReferences
Kutlubay Z, Engin B, Bairamov O, Tuzun Y. Acanthosis nigricans: A fold (intertriginous) dermatosis. Clin Dermatol. 2015; 33(4):466-70.
Videira-Silva A, Albuquerque C, Fonseca H. Acanthosis nigricans as a clinical marker of insulin resistance among overweight adolescents. Ann Pediatr Endocrinol Metab. 2019; 24(2):99-103.
Maguolo A, Maffeis C. Acanthosis nigricans in childhood: A cutaneous marker that should not be underestimated, especially in obese children. Acta Paediatr. 2020; 109(3):481-7
Ozlu E, Uzuncakmak TK, Takır M, Akdeniz N, Karadag AS. Comparison of cutaneous manifestations in diabetic and nondiabetic obese patients: A prospective, controlled study. North Clin Istanb. 2018; 5(2):114-9.
Maitra S K, Rowland Payne C M E. The obesity syndrome and acanthosis nigricans. Acanthosis nigricans is a common cosmetic problem providing epidemiological clues to the obesity syndrome, the insulin-resistance syndrome, the thrifty metabolism, dyslipidaemia, hypertension and diabetes mellitus type II. J Cosmet Dermatol. 2004; 3(4):202-10.
Bahadursingh S, Mungalsingh C, Seemungal T, Teelucksingh S. Acanthosis nigricans in type 2 diabetes: prevalence, correlates and potential as a simple clinical screening tool - a cross-sectional study in the Caribbean. Diabetol Metab Syndr. 2014; 6:77.
Burke J P, Hale D E, Hazuda H P, Stern M P. A quantitative scale of acanthosis nigricans. Diabetes Care. 1999; 22(10):1655-9.
Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004; 5(3):199-203.
Hodak E, Gottlieb AB, Anzilotti M, Krueger JG. The insulin-like growth factor 1 receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: correlation of increased expression with epidermal hyperplasia. J Invest Dermatol. 1996; 106(3):564-70.
Muguet Guenot L, Aubert H, Isidor B, Toutain A, Mazereeuw- Hautier J, Collet C, Bourrat E, Denis Musquer M, Barbarot S. Acanthosis nigricans, hypochondroplasia, and FGFR3 mutations: Findings with five new patients, and a review of the literature. Pediatr Dermatol. 2019; 36(2):242-6.
Krawczyk M, Mykala-Ciesla J, Kolodziej-Jaskula A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn. 2009; 119(3):180-3.
Ellis DL, Kafka SP, Chow JC, Nanney LB, Inman WH, McCadden ME, King LE Jr. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trelat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med. 1987; 317(25):1582-7.
Koyama S, Ikeda K, Sato M, Shibahara K, Yuhara K, Fukutomi H. Transforming growth factor-alpha (tgf alpha)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of tgf alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol. 1997; 32(1):71-7.
Wilgenbus K, Lentner A, Kuckelkorn R, Handt S, Mittermayer C. Further evidence that acanthosis nigricans maligna is linked to enhanced secretion by the tumour of transforming growth factor alpha. Arch Dermatol Res. 1992; 284(5):266-70.
Mueller N, Sassa T, Morales-Gonzalez S, Schneider J, Salchow DJ, Seelow D, Knierim E, Stenzel W, Kihara A, Schuelke M. De novo mutation in ELOVL1 causes ichthyosis, acanthosis nigricans, hypomyelination, spastic paraplegia, high-frequency deafness and optic atrophy. J Med Genet. 2019; 56(3):164-75.
Mailler-Savage EA, Adams BB. Exogenous insulin-derived Acanthosis nigricans. Arch Dermatol. 2008; 144(1):126-7.
Kudo-Watanuki S, Kurihara E, Yamamoto K, Mukai K, Chen KR. Coexistence of insulin-derived amyloidosis and an overlying acanthosis nigricans-like lesion at the site of insulin injection. Clin Exp Dermatol. 2013; 38(1):25-9
Lane SW, Manoharan S, Mollee PN. Palifermin-induced acanthosis nigricans. Intern Med J. 2007; 37(6):417-8.
Hassan I, Altaf H, Yaseen A. Rabson-mendenhall syndrome. Indian J Dermatol. 2014; 59(6):633.
Berk D R, Spector E B, Bayliss S J. Familial acanthosis nigricans due to K650T FGFR3 mutation. Arch Dermatol. 2007;143(9):1153-6.
Fu J, Zhao Y, Wang T, Zhang Q, Xiao X. Acanthosis nigricans in a Chinese girl with FGFR3 K650 T mutation: a case report and literature review. BMC Med Genet 2019; 20:8.
Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med. 1989; 87(3):269-72.
Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol. 1992; 128(7):941-4.
Dassanayake AS, Kasturiratne A, Niriella MA, Kalubovila U, Rajindrajith S, de Silva AP, Kato N, Wickremasinghe AR, de Silva HJ. Prevalence of Acanthosis Nigricans in an urban population in Sri Lanka and its utility to detect metabolic syndrome. BMC Res Notes. 2011; 4:25.
Mukhtar Q, Cleverley G, Voorhees RE, McGrath JW. Prevalence of acanthosis nigricans and its association with hyperinsulinemia in New Mexico adolescents. J Adolesc Health. 2001; 28(5):372-6.
Stoddart ML, Blevins KS, Lee ET, Wang W, Blackett PR. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. Diabetes Care. 2002; 25(6):1009-14.
Ng HY, Young JH, Huen KF, Chan LT. Acanthosis nigricans in obese Chinese children. Hong Kong Med J. 2014; 20(4):290-6.
Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol. 2007; 57(3):502-8.
Barbato M T, Criado P R, Silva A K, Averbeck E, , Guerine M B, Sa N B,. Association of acanthosis nigricans and skin tags with insulin resistance. Anais Brasileiros de Dermatologia, 2012; 87(1): 97-104.
Curth HO. Classification of acanthosis nigricans. Int J Dermatol. 1976; 15(8):592-3.
Hernandez-Perez E. On the classification of acanthosis nigricans. J Dermatol. 1984; 23(9):605-6.
Popa M, Popa AC, Tanase C and Gheorghisan-Galateanu A: Acanthosis nigricans: To be or not to be afraid (Review). Oncol Lett 2019;17: 4133-8.
Gonzalez-Saldivar G, Rodriguez-Gutierrez R, Ocampo-Candiani J, Gonzalez-Gonzalez JG, Gomez-Flores M. Skin manifestations of insulin resistance: From a biochemical stance to a clinical diagnosis and management. Dermatol Ther (Heidelb) 2017; 7:37-51.
Ng HY. Acanthosis nigricans in obese adolescents: prevalence, impact, and management challenges. Adolesc Health Med Ther. 2017; 8:1-10.
Panda S, Das A, Lahiri K, Chatterjee M, Padhi T, Rathi S, Dhar S, Sarma N. Facial acanthosis nigricans: A morphological marker of metabolic syndrome. Indian J Dermatol. 2017; 62:591-7.
Jeong KH, Oh SJ, Chon S, Lee MH. Generalized acanthosis nigricans related to type B insulin resistance syndrome: A case report. Cutis. 2010; 86:299–302.
Jeong JS, Lee JY, Yoon TY. Unilateral nevoid acanthosis nigricans with a submammary location. Ann Dermatol. 2011; 23:95-7.
Das A, Bhattacharya S, Kumar P, Gayen T, Roy K, Das NK, Gharami RC. Unilateral nevoid acanthosis nigricans: Uncommon variant of a common disease. Indian Dermatol Online J. 2014; 5(Suppl 1): S40-3.
Krishnaram AS. Unilateral nevoid acanthosis nigricans. Int J Dermatol 1991; 30:452-3.
Innaurato S, Brierley GV, Grasso V, Massimi A, Gaudino R, Sileno S, Bernardini S, Semple R, Barbetti F. Severe insulin resistance in disguise: A familial case of reactive hypoglycemia associated with a novel heterozygous INSR mutation. Pediatr Diabetes. 2018; 19:670-4.
Kondo Y, Umegaki N, Terao M, Murota H, Kimura T, Katayama I. A case of generalized acanthosis nigricans with positive lupus erythematosus-related autoantibodies and antimicrosomal antibody: Autoimmune acanthosis nigricans? Case Rep Dermatol. 2012; 4:85-91.
Kim HN, Fesseha B, Anzaldi L, Tsao A, Galiatsatos P, Sidhaye A. Antibody-mediated extreme insulin resistance: A Report of three cases. Am J Med. 2018; 131:102-6.
Sturner RA, Denning S, Marchase P. Acanthosis nigricans and autoimmune reactivity. JAMA. 1981; 246:763-5.
Yu Q, Li XL, Ji G, Wang Y, Gong Y, Xu H, Shi YL. Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. World J Surg Oncol. 2017;15(1):208.
Brinca A, Cardoso JC, Brites MM, Tellechea O, Figueiredo A. Florid cutaneous papillomatosis and acanthosis nigricans maligna revealing gastric adenocarcinoma. An Bras Dermatol. 2011; 86(3):573-7.
Yeh JS, Munn SE, Plunkett TA, Harper PG, Hopster DJ, du Vivier AW. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol. 2000; 42(2 Pt 2):357-62.
Antonio JR, TrÃdico LA, Antonio CR. Malignant Acanthosis nigricans associated with early diagnosis of liver cancer. An Bras Dermatol. 2018; 93(4):616-7.
Scully C, Barrett WA, Gilkes J, Rees M, Sarner M, Southcott RJ. Oral acanthosis nigricans, the sign of Leser-Trelat and cholangiocarcinoma. Br J Dermatol. 2001; 145: 506-7.
Jacobs MI, Rigel DS. Acanthosis nigricans and the sign of Leser-Trelat associated with adenocarcinoma of the gallbladder. Cancer. 1981; 48: 325-8.
Kaminska-Winciorek G, Brzezinska-Wcisło L, Lis-Swiety A, Krauze E. Paraneoplastic type of acanthosis nigricans in patient with hepatocellular carcinoma. Adv Med Sci. 2007; 52:254-6.
Gunduz K, Coban M, Ozturk F, Ermertcan AT. Malignant acanthosis nigricans associated with ileocecal adenocarcinoma. Cutan Ocul Toxicol. 2013; 32(2):173-5.
Mukherjee S, Pandit S, Deb J, Dattachaudhuri A, Bhuniya S, Bhanja P. A case of squamous cell carcinoma of lung presenting with paraneoplastic type of acanthosis nigricans. Lung India. 2011; 28(1):62-4.
Deen J, Moloney T, Burdon-Jones D. Severe, Malignant Acanthosis Nigricans Associated with Adenocarcinoma of the Endometrium in a Young Obese Female. Case Rep Dermatol. 2017; 9(1):30-7.
Longhsore S, Taylor J, Kennedy A, et al. Malignant acanthosis nigricans and endometrioid adenocarcinoma of the parametrium: the search for malignancy. Am Acad Dermatol. 2003; 49:541–3.
Mekhail TM, Markman M. Acanthosis nigricans with endometrial carcinoma: case report and review of the literature. Gynecol Oncol. 2002; 84: 332-4.
Kebria MM, Belinson J, Kim R, Mekhail TM. Malignant acanthosis nigricans, tripe palms and the sign of Leser-Trelat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature. Gynecol Oncol. 2006; 101(2):353-5.
Olek-Hrab K, Silny W, Zaba R, Osmola-Mankowska A, Mackiewicz-Wysocka M, Dańczak-Pazdrowska A. Co-occurrence of acanthosis nigricans and bladder adenocarcinoma – case report. Contemp Onkol (Pozn) 2013; 17:327-30.
Mohrenschlager M, Vocks E, Wessner DB, Nahrig J, Ring J. Tripe palms and malignant acanthosis nigricans: cutaneous signs of imminent metastasis in bladder cancer? Journ of Urol. 2001; 165:1629-30.
Marschner ML, Reinhardt JF. Malignant acanthosis nigricans in rectal adenocarcinoma. Del Med J. 2011; 83(8):247-9.
Tammaro A, Giulianelli V, Parisella F, Persechino S. Bilaterally mammary acanthosis nigricans as paraneoplastic manifestation of prostate adenocarcinoma. G Ital Dermatol Venereol. 2016; 151(5):578-9.
Brantsch KD, Moehrle M. Acanthosis nigricans in a patient with sarcoma of unknown origin. J Am Acad Dermatol. 2010; 62(3):527-8.
Dainichi T, Moroi Y, Duan H, Urabe K, Koga T, Miyazono M, Sasaki T, Hashimoto T, Furue M. Paraneoplastic acanthosis nigricans and silent meningioma producing transforming growth factor-alpha. Eur J Dermatol. 2008; 18(6):721-2.
Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology. 1994;189(2):203-6.
Hartman R, Defelice T, Tzu J, Meehan S, Sanchez M. Acanthosis nigricans in the setting of niacin therapy. Dermatol Online J. 2011; 17:11
Buzasi K, Sapi Z, Jermendy G. Acanthosis nigricans as a local cutaneous side effect of repeated human insulin injections. Diabetes Res Clin Pract. 2011; 94(2): e34-e36.
Brodell JD Jr, Cannella JD, Helms SE. Case report: acanthosis nigricans resulting from repetitive same-site insulin injections. J Drugs Dermatol. 2012;11(12): e85-e87.
Sawatkar GU, Dogra S, Bhadada SK, Kanwar AJ. Acanthosis nigricans - an uncommon cutaneous adverse effect of a common medication: Report of two cases. Indian J Dermatol Venereol Leprol. 2013; 79:553.
Bishnoi A, Parsad D. Velvety hyperpigmentation on hands and feet of a young girl: Acral acanthosis nigricans. J Cutan Med Surg. 2018; 22:323.
Anand V, Das A, Kumar P, Kumar R, Hassan S. Acral acanthosis nigricans (acral acanthotic anomaly). Indian Dermatol Online J. 2014; 5(Suppl 2): S140–S141.
Tabandeh H, Gopal S, Teimory M, Wolfensberger T, Luke I K, Mackie I, Dilly N. Conjunctival involvement in malignancy-associated acanthosis nigricans. Eye (Lond). 1993; 7(Pt 5):648-51.
Lee HW, Suh HS, Choi JC, Lee M W, Choi J H, Moon K C, Koh J K. Hyperkeratosis of the nipple and areola as a sign of malignant acanthosis nigricans. Clin Exp Dermatol. 2005; 30(6):721-2.
Stawczyk-Macieja M, Szczerkowska-Dobosz A, Nowicki R, Majewska H, Dubowik M, Sokołowska-Wojdylo M. Malignant acanthosis nigricans, florid cutaneous papillomatosis and tripe palms syndrome associated with gastric adenocarcinoma. Postepy Dermatol Alergol. 2014; 31(1):56-8.
Zhang N, Qian Y, Feng AP. Acanthosis nigricans, tripe palms, and sign of Leser-Trélat in a patient with gastric adenocarcinoma: case report and literature review in China. Int J Dermatol. 2015; 54(3):338-42.
da Costa França AF, Siqueira NS, Carvalheira JB, Saad MJ, Souza EM. Acanthosis nigricans, tripe palms and the sign of Leser-Trelat in a patient with a benign hepatic neoplasia. J Eur Acad Dermatol Venereol. 2007; 21(6):846-8.
Schwartz RA. Acanthosis nigricans, florid cutaneous papillomatosis and the sign of Leser-Trelat. Cutis. 1981; 28:319-34.
Gheeraert P, Goens J, Schwartz RA, Lambert WC, Schroeder F, Debusscher L. Florid cutaneous papillomatosis, malignant acanthosis nigricans, and pulmonary squamous cell carcinoma. Int J Dermatol. 1991; 30(3):193-7.
Puri N. A study of pathogenesis of acanthosis nigricans and its clinical implications. Indian J Dermatol. 2011; 56:678-83.
Devpura S, Pattamadilok B, Syed ZU, Vemulapalli P, Henderson M, Rehse S J, Hamzavi I, Lim H W, Naik R. Critical comparison of diffuse reflectance spectroscopy and colorimetry as dermatological diagnostic tools for acanthosis nigricans: a chemometric approach. Biomed Opt Express. 2011; 2(6):1664-73.
Pattamadilok B, Devpura S, Syed ZU, Agbai O N, Vemulapalli P, Henderson M, Rehse S J, Mahmoud B H, Lim H W, Naik R, Hamzavi I H. Quantitative skin color measurements in acanthosis nigricans patients: colorimetry and diffuse reflectance spectroscopy. Photodermatol Photoimmunol Photomed. 2012; 28(4):213-5.
Rodriguez-Gutierrez R, Salcido-Montenegro A, Gonzalez-Gonzalez JG. Early Clinical Expressions of Insulin Resistance: The Real Enemy to Look For. Diabetes Ther. 2018; 9(1):435-8.
Wallace CA, Pichardo RO, Yosipovitch G, Hancox J, Sangueza OP. Granular parakeratosis: a case report and literature review. J Cutan Pathol. 2003; 30(5):332-35.
McCormack CJ, Cowen P. Haber's syndrome. Australas J Dermatol. 1997; 38(2):82-84.
Lim JH, Tey HL, Chong WS. Confluent and reticulated papillomatosis: diagnostic and treatment challenges. Clin Cosmet Investig Dermatol. 2016; 9:217-23.
Wu Y H, Lin Y C. Generalized Dowling-Degos disease. J Am Acad Dermatol. 2007; 57:327-34.
Kocaturk E, Kavala M, Zindanci I, Zemheri E, Koc MK, Sarigul S. Reticulate acropigmentation of Kitamura: report of a familial case. Dermatol Online J. 2008; 14(8):7.
Hsu S, Chen JY, Subrt P. Becker's melanosis in a woman. J Am Acad Dermatol 2001; 45: S195-S196.
Dellion S, Morel P, Vignon-Pennamen D, Felten A. Erythrasma owing to an unusual pathogen. Arch Dermatol. 1996; 132(6):716-7.
Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011; 4(5):32-8.
Kaminska-Winciorek G, Wydmanski J, Scope A, Argenziano G, Zalaudek I. "Neglected nipples": acanthosis nigricans-like plaques caused by avoidance of nipple cleansing. Dermatol Pract Concept. 2014;4(3):81-84.
Pirgon O, Sandal G, Gokcen C, Bilgin H, Dündar B. Social anxiety, depression and self-esteem in obese adolescent girls with acanthosis nigricans. J Clin Res Pediatr Endocrinol. 2015; 7(1):63-8.
Huang Y, Chen J, Yang J, Song K, Wang X, Cheng X, Qu S. Evaluation of depressive symptoms in obese patients with or without acanthosis nigricans. Hormones (Athens). 2015; 14(3):417-24.
Ghosh S, Roychowdhury B, Mukhopadhyay S, Chowdhury S. Clearance of acanthosis nigricans associated with insulinoma following surgical resection. QJM. 2008; 101(11):899-900.
Patel NU, Roach C, Alinia H, Huang WW, Feldman SR. Current treatment options for acanthosis nigricans. Clin Cosmet Investig Dermatol. 2018; 11:407-3.
Lahiri K, Malakar S. Topical tretinoin in acanthosis nigricans. Indian J Dermatol Venereol Leprol. 1996; 62(3):159-61.
Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol. 1991;127(8):1139-40.
Schwartz RA. Efficacy of topical 0.1% adapalene gel for use in the treatment of childhood acanthosis nigricans: a pilot study. Dermatol Ther. 2015; 28(4):266.
Treesirichod A, Chaithirayanon S, Wongjitrat N, Wattanapan P. The efficacy of topical 0.1% adapalene gel for use in the treatment of childhood acanthosis nigricans: a pilot study. Indian J Dermatol. 2015; 60(1):103.
Treesirichod A, Chaithirayanon S, Wongjitrat N. Comparison of the efficacy and safety of 0.1% adapalene gel and 0.025% tretinoin cream in the treatment of childhood acanthosis nigricans. Pediatr Dermatol. 2019; 36(3):330-4.
Treesirichod A, Chaithirayanon S, Chaikul T, Chansakulporn S. The randomized trials of 10% urea cream and 0.025% tretinoin cream in the treatment of acanthosis nigricans. J Dermatolog Treat. 2020; 1:6.
Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. Cutis. 2003; 71(1):33-34.
Adigun CG, Pandya AG. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream. J Eur Acad Dermatol Venereol. 2009; 23(4):486-7.
Romo A, Benavides S. Treatment options in insulin resistance obesity related acanthosis nigricans. Ann Pharmacother. 2008; 42(7-8):1090-4.
Bohm M, Luger TA, Metze D. Treatment of mixed-type acanthosis nigricans with topical calcipotriol. Br J Dermatol. 1998; 139(5):932-4.
Lee H-W, Chang S-E, Lee M-W, Choi J-H, Moon K-C, Koh J-K. Hyperkeratosis of the nipple associated with acanthosis nigricans: treatment with topical calcipotriol. J Am Acad Dermatol. 2005; 52(3):529-30.
Gregoriou S, Anyfandakis V, Kontoleon P, Christofidou E, Rigopoulos D, Kontochristopoulos G. Acanthosis nigricans associated with primary hypogonadism: successful treatment with topical calcipotriol. J Dermatolog Treat. 2008;19(6):373-5.
Phiske MM. An approach to acanthosis nigricans. Indian Dermatol Online J. 2014; 5(3):239-49.
Zayed A, Sobhi RM, Abdel Halim DM. Using trichloroacetic acid in the treatment of acanthosis nigricans: a pilot study. J Dermatolog Treat. 2014; 25(3):223-5.
Katz RA. Treatment of acanthosis nigricans with oral isotretinoin. Arch Dermatol. 1980;116(1):110-1.
Walling HW, Messingham M, Myers LM, Mason CL, Strauss JS. Improvement of acanthosis nigricans on isotretinoin and metformin. J Drugs Dermatol. 2003; 2(6):677-81.
Ozdemir M, Toy H, MevlitoÄŸlu I, Demirkesen C. Generalized idiopathic acanthosis nigricans treated with acitretin. J Dermatolog Treat. 2006;17(1):54-6.
Tankova T, Koev D, Dakovska L, Kirilov G. Therapeutic approach in insulin resistance with acanthosis nigricans. Int J Clin Pract. 2002; 56(8):578-81.
Giri D, Alsaffar H, Ramakrishnan R. Acanthosis Nigricans and Its Response to Metformin. Pediatr Dermatol. 2017; 34(5): e281-e282.
Wasniewska M, Arrigo T, Crisafulli G, Lombardo F, Messina M F, Salzano G, Valenzise M, De Luca F. Recovery of acanthosis nigricans under prolonged metformin treatment in an adolescent with normal weight. J Endocrinol Invest. 2009; 32(11):939-40.
Bellot-Rojas P, Posadas-Sanchez R, Caracas-Portilla N, Zamora-Gonzalez J, Cardoso-Saldana G, Jurado-Santacruz F, Posadas-Romero C. Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. J Drugs Dermatol. 2006; 5(9):884-9.
Sherertz EF. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Arch Dermatol. 1988;124(7):1094-6.
Epstein E. Podophyllin therapy in acanthosis nigricans. J Invest Dermatol. 1951; 17(1):7.
Kapoor S. Diagnosis and treatment of Acanthosis nigricans. Skinmed. 2010; 8(3):161-5.
